Neutral and cationic square-planar Pd(II) complexes containing the β-phosphonato-phosphine ligand rac-Ph2PCH(Ph)P(O)(OEt)2 (1) or the new α-silyl-phosphonato-phosphine ligand Ph2PCH(SiMe3)P(O)(OMe)2 (4) have been prepared. Reaction of 4 with [Pd(μ-Cl)(dmba)]2 (dmba = o-C6H4CH2NMe2) afforded an equilibrium mixture of [Pd(dmba){Ph2PCH(SiMe3)P(O)(OMe)2}]Cl (5) and [PdCl(dmba){Ph2PCH(SiMe3)P(O)(OMe)2}] (5′), which illustrates the hemilabile behavior of the ligand in this system. From the stepwise insertion reaction of CO and ethylene into the Pd−C bond of [PdCl(Me){Ph2PCH(Ph)P(O)(OEt)2}] (2a), the metallacyclic complex [ Pd{CH2CH2C(O)Me{Ph2PCH(Ph)P(O)(OEt)2][BF4] (10) was obtained which features the first acetyl−ethylene coupling product containing a phosphine−phosphonate ligand. Chloride abstraction from 2a led to the cationic complex [PdMe(NCMe){Ph2PCH(Ph)P(O)(OEt)2}][BF4] (8), which reacted sequentially with CO and methyl acrylate to afford [P d{CH[C(O)OMe][CH2C(O)Me]}{Ph2PCH(Ph)P(O)(OEt)2}][BF4] (11). The reaction between 8 and the P,O-ligand Ph2PNHC(O)Me resulted in an equilibrated ligand exchange where the heteroleptic system is preferred over the mixture of the two homoleptic complexes. The complexes 2a and 10·1/2CHCl3 have been characterized by X-ray diffraction and represent rare examples of crystal structures showing a (diethyl)methylphosphonate ligand coordinated to a metal center.
The bis(diphenylphosphino)methane-phosphonate-based (dppm-phosphonate) ligands (Ph(2)P)(2)CHP(O)(OR)(2) (R = Me, L(1); R = Ph, L(2)) form metal complexes by selective coordination of the diphosphine moiety to Pd(II) and Ni(II) centers. The formation of complexes containing the chelating, deprotonated form of ligand L(1) or L(2) occurred when basic ligands were present in the precursor complex, such as Me or dmba (on Pd(II)) or acac (on Ni(II)). The Cu(I) complex [CuL(1)](2)(BF(4))(2) (9) was obtained that is suggested to be dinuclear, each Cu(I) being chelated by a phosphine and a P=O donor and further bound to the phosphine group of another ligand. The crystal structures of the mononuclear complexes [PdCl(2){(Ph(2)P)(2)CHP(O)(OMe)(2)-P,P}] (2a), [PdCl(2){(Ph(2)P)(2)CHP(O)(OPh)(2)-P,P}] (2b), [Pd{(Ph(2)P)(2)CP(O)(OMe)(2)-P,P}(2)] (6a) in 6a.2CH(2)Cl(2), [Pd{(Ph(2)P)(2)CP(O)(OPh)(2)-P,P}(2)] (6b), [Ni{(Ph(2)P)(2)CP(O)(OMe)(2)-P,P}(2)] (10a) in 10a.4CHCl(3), [Ni{(Ph(2)P)(2)CP(O)(OPh)(2)-P,P}(2)] (10b) in 10b.4CHCl(3), [NiCl(2){(Ph(2)P)(2)CHP(O)(OMe)(2)-P,P}] (11a) in 11a.CHCl(3) and of the dinuclear complexes [Pd(mu-Cl){(Ph(2)P)(2)CP(O)(OMe)(2)-P,P}](2) (7a) and [Pd(mu-Cl){(Ph(2)P)(2)CP(O)(OPh)(2)-P,P}](2) (7b) have been determined by X-ray diffraction. The complexes [Ni{(Ph(2)P)(2)CC(O)NPh(2)-P,P}(2)] (13) and [Ni{Ph(2)PC(Ph)P(O)(OEt)(2)-P,O}(2)] (15) were prepared by reaction of [Ni(acac)(2)] with the known, neutral ligands (Ph(2)P)(2)CHC(O)NPh(2) and Ph(2)PCH(Ph)P(O)(OEt)(2), respectively. The Ni(II) complexes were evaluated for the catalytic oligomerization of ethylene and afforded similar results when AlEtCl(2) was used as cocatalyst. Complexes 11a,b were the most active, with a turnover frequency (TOF) of 78 300 mol of C(2)H(4)/(mol of Ni)h) for complex 11b in the presence of 10 equiv of AlEtCl(2) and showed a high selectivity for C(4) and C(6) olefins with up to 93% C(4) for 10a in the presence of 6 equiv AlEtCl(2), whereas when only 3 equiv cocatalyst was used with 10a, 64% trimers were observed. In the presence of methylalumoxane (MAO) as cocatalyst, precatalysts 10a,b, 11a,b, and 15 gave moderate TOFs, up to 11,660 mol of C(2)H(4)/(mol of Ni)h) for complex 11a with 400 equiv of MAO. Mostly ethylene dimers were formed but up to 39% trimers were observed with 10a in the presence of 400 equiv MAO.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.